Goldman Sachs Group Inc Satsuma Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 May 14, 2024	BUY	$2.59 - $4.3 $26,182 - $43,468	10,109 New	10,109 $42,000
Q2 2022 Aug 15, 2022	SELL	$2.59 - $4.3 $67 - $111	-26 Reduced 0.26%	10,109 $42,000
Q1 2022 May 16, 2022	SELL	$3.78 - $5.32 $748 - $1,053	-198 Reduced 1.92%	10,135 $39,000
Q4 2021 Feb 14, 2022	SELL	$4.15 - $6.24 $3,320 - $4,992	-800 Reduced 7.19%	10,333 $46,000
Q3 2021 Nov 10, 2021	BUY	$4.54 - $7.17 $50,543 - $79,823	11,133 New	11,133 $52,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.